Society guideline links: Malignant hyperthermia

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●Clinical Pharmacogenetics Implementation Consortium (CPIC): Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes (2019, updated 2023)

United States

●Malignant Hyperthermia Association of the United States (MHAUS): Consensus statement on unresolved clinical questions concerning the management of patients with malignant hyperthermia (2019)

●Society for Ambulatory Anesthesia (SAMBA) and American Society of Anesthesiologists (ASA): Position statement on the malignant hyperthermia-susceptible adult patient and ambulatory surgery center (2019)

●Association of Surgical Technologists (AST): Guidelines for best practices for treatment of surgical patients experiencing malignant hyperthermia in the operating room (2005, revised 2018)

Europe

●European Malignant Hyperthermia Group (EMHG): Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients (2021)

●EMHG: Guidelines on availability of dantrolene for the management of malignant hyperthermia crises (2020)

●EMHG: Recommendations on occupational exposure to volatile anaesthetics (2020)

●EMHG: Recommendations on malignant hyperthermia during pregnancy (2019)

●EMHG: Recommendations for perioperative management of MH suspected or susceptible patients (2018)